Sanofi | GenomeWeb

Sanofi

The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.

Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.

The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.

The study used a modified version of Myriad RBM's DiscoveryMAP immunoassay panel to measure levels of 237 proteins in blood samples from 8,401 patients.

The pharma firm joins Pfizer Canada and AstraZeneca in the National Access Project, which tests tumors for mutations to match patients with potential therapies.

The two methods could shorten the detection time by eliminating the need to amplify the virus with in vitro cell culture.

The data show that RG-012 can enhance the effect of Sanofi's kidney protectant ramipril and suggest the microRNA drug might have use in other chronic kidney diseases.

Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013

NEW YORK (GenomeWeb) — Illumina has partnered with AstraZeneca, Janssen Biotech, and Sanofi to develop a universal next-generation sequencing-based oncology test system for multi-analyte companion diagnostics, the company said today.

Pages

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.